Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ February 10, 2019 A bug in the system – the difficulties of linking the... June 2, 2021 FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer May 10, 2021 Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... October 4, 2022 Load more HOT NEWS 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer Searching for novel connections in cancer metabolism Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations
